NASD · Healthcare · Medical Devices · USA
Pulmonx Corp is a micro cap company (market value under $300 million) in the Medical Devices industry.
Pulmonx Corp develops devices to treat severe emphysema patients through a less invasive approach than surgery. The company's solution combines the Zephyr Endobronchial Valve, Chartis assessment system and LungTraX Platform to help identify and treat eligible patients. Pulmonx sells directly to interventional pulmonologists in the United States and through distributors internationally.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Pulmonx Corp stock.
Overvalued: intrinsic value $0.61 per share, market price $2.73, margin of safety -349.3% (as of 2026-11-17).
Its liquidation floor, current assets minus every liability, values the shares at $0.61; the price of $2.73 is 349% above that value.
1 more funds hold it; the full list is part of the paid plan.
All 140 Medical Devices stocks
49 more in this industry show a wider margin of safety.
LUNG is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $0.61; the price of $2.73 is 349% above that value.
$0.61 per share (as of the 2026-11-17 close), against a market price of $2.73. That is a margin of safety of -349.3%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.